In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457

Antimicrobial Agents and Chemotherapy
2007.0

Abstract

RWJ-416457, an investigational pyrrolopyrazolyl-substituted oxazolidinone, inhibited the growth of linezolid-susceptible staphylococci, enterococci, and streptococci at concentrations of < or =4 microg/ml, generally exhibiting two- to fourfold-greater potency than that of linezolid. Time-kill studies demonstrated bacteriostatic effects for both RWJ-416457 and linezolid.

Knowledge Graph

Similar Paper

In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457
Antimicrobial Agents and Chemotherapy 2007.0
In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci
Antimicrobial Agents and Chemotherapy 2007.0
In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457
Antimicrobial Agents and Chemotherapy 2009.0
Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-ResistantStaphylococcus aureus
Antimicrobial Agents and Chemotherapy 2009.0
Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones
Bioorganic &amp; Medicinal Chemistry Letters 2003.0
Synthesis and in vitro activity of novel isoxazolyl tetrahydropyridinyl oxazolidinone antibacterial agents
Bioorganic &amp; Medicinal Chemistry Letters 2003.0
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials
Bioorganic &amp; Medicinal Chemistry Letters 2006.0
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones
Bioorganic &amp; Medicinal Chemistry Letters 2007.0
Synthesis and antibacterial activity of arylpiperazinyl oxazolidinones with diversification of the N-substituents
Bioorganic &amp; Medicinal Chemistry Letters 2004.0
Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Part II
Bioorganic &amp; Medicinal Chemistry Letters 2011.0